Twist Bioscience Corp
Twist Bioscience Corporation is a synthetic biology company that manufactures DNA using a proprietary silicon-based platform. Its products serve markets including genetic research, diagnostics, industrial biotechnology and therapeutic development, supplying synthetic DNA, oligos and related services to biotech and pharmaceutical customers. Investors should know Twist is positioned in an emerging, high-growth segment of life sciences where demand for custom DNA and sequencing‑ready products can increase as genomics, cell and gene therapies, and diagnostics expand. The company has pursued partnerships and commercial contracts to broaden revenue channels, but still faces typical biotech execution risks: scaling manufacturing, achieving sustained profitability and managing R&D and capital needs. As a small-cap equity (market cap roughly $2.0bn), TWST can be more volatile than large-cap peers. This summary is for educational purposes only and not personal financial advice; investors should check the company’s latest results, cash runway and competitive landscape before deciding suitability for their portfolio.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Twist Bioscience's stock with a target price of $39.12, indicating strong growth potential.
Financial Health
Twist Bioscience is showing strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TWST
Activist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketSynthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: June 17, 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Synthetic biology exposure
Twist offers exposure to the expanding market for engineered DNA used in therapeutics and diagnostics, though growth can be uneven and competition is strong.
Partnerships and customers
Collaborations with pharma and diagnostics firms can diversify revenue and validate technology, but customer concentration and contract timing remain factors to monitor.
Execution and cash
Scaling manufacturing and moving toward sustained profitability are key milestones; capital requirements and cash runway deserve careful review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
